R
Regimmune
A biotechnology company producing immune-regulatory therapeutics for life-threatening diseases and debilitating disorders
About Regimmune
REGiMMUNE Corporation is a clinical-stage biopharmaceutical company specializing in the development of innovative immunotherapies aimed at treating rare diseases and cancer. The company leverages decades of scientific research on regulatory T cells (Tregs), which are critical for controlling immune responses. By harnessing these cells, REGiMMUNE aims to induce immune tolerance and achieve potent anti-tumor responses. The company's approach involves using a synthetic small molecule formulated with liposome technology to control the expansion of Tregs, thereby facilitating transplantation tolerance and alleviating autoimmune disease manifestations.
REGiMMUNE operates primarily in the biopharmaceutical market, serving patients with rare diseases and cancer. The business model is centered around developing and commercializing its proprietary immunotherapy treatments. Revenue is generated through a combination of product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2006
- Headquarters
- Tokyo, Japan
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 74.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Health Diagnostics, Spinout, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b, b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Apr 2017 | $6M | $46M | Mitsubishi UFJ Capital · Hiroshima Venture Capital · Iyogin Capital · Miyako Capital | ↗ |
| SERIES DOther financing | Feb 2014 | $9.2M | $37M | Mitsubishi UFJ Capital · Mizuho Capital · Japan Asia Investment · Nippon Venture Capital | — |
Growth signals
Latest recorded traffic for Regimmune is 2.4K monthly website visits, up 293.4% over the last three months. Regimmune's team grew 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Japan Asia Investment
Ant Capital Partners
Japan Science and Technology Agency
Series A4 investors entered at this stage
- FCFund Creation
Mitsubishi UFJ Capital- NCNew Cycle Capital
- YDYasuda Enterprise Development
Series B and later11 investors entered at this stage
SMBC Venture Capital
Daiwa Securities Group
Shinkin Capital- MEMedinet
Nippon Venture Capital
Mizuho Capital
Hiroshima Venture Capital
Iyogin Capital
Miyako Capital
Oita Venture Capital- KCKyoritsu Captal
Other known investors1 additional known investor
Kyoto University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Regimmune on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Regimmune’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.